Controversial laser heart procedures find little favour among US MCAC (Medicare coverage advisory committee) panel
This article was originally published in Clinica
Executive Summary
There is too little evidence to judge the potential health benefits of a procedure that uses lasers to drill holes in the heart's myocardium following coronary artery bypass surgery, a panel of experts told Medicare last week.
You may also be interested in...
The First Sham-Controlled PCI Trial In Stable Patients
More details about the controversial ORBITA trial.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.